Clinical Trials - Regulatory - Oncology
FDA's Vision for Multiregional Clinical Trials in Oncology
|
FDA Veteran Paz Vellanki, MD, joins Precision to become one of 3 ex-FDA oncology leaders supporting clients
CMO Confidential
The FDA’s 2025 approvals of Dordaviprone, Enhertu and Itvisma highlight shifting regulatory and development expectations heading into 2026. In this CMO Confidential video, watch Precision’s Chief Medical Officer and former FDA Director, Division of Oncology 2, Harpreet Singh, MD, explain what these landmark decisions mean for sponsors preparing for upcoming FDA submissions in oncology and rare diseases.
Stay informed with the latest insights from Precision experts, who share insights, trends, and success stories from the front lines of clinical research.
Clinical Trials - Regulatory - Oncology
Discover
Leverage an integrated infrastructure that reduces the inefficiencies inherent in complex development. Integrate lab and trial execution to increase speed to market. Incorporate manufacturing expertise for advanced therapies to ensure scalability. Precision brings a holistic view to your program's unique needs.
Award-winning CRO with deep oncology and rare disease expertise
Discover Explore
Exceptional translational and biomarker sciences with global central lab services